Introduction
African Americans (AA) are twice as likely to be diagnosed with multiple myeloma (MM) and the age-adjusted death rate is twice as high as that of Caucasian Americans (CA). 1 Multiple variables, such as diet, tobacco, obesity, socioeconomic status and access to medical care, have been hypothesized to be related to the differences in the outcome between AA and CA. [2] [3] [4] [5] High prevalence of monoclonal gammopathy has been reported in AA as well. 6 Auto-SCT is an established treatment modality for newly diagnosed patients with MM. 7, 8 However, there is only limited literature available regarding the outcomes after auto-SCT in AA with MM. Furthermore, there is no study addressing the influence of pre and post transplant prognostic variables of known importance for CA on the outcomes in AA. Saraf et al. 9 reported a superior median event-free survival of 21 months in 38 AA patients compared with 12 months in 32 non-AA patients after auto-SCT for MM; (P ¼ 0.02). 9 In a similar analysis, Verma et al. 10 reported a prolonged median PFS and OS of 60.5 and 95.2 months, respectively, in 36 AA patients with MM after auto-SCT compared with a PFS and OS of 43.7 and 68.5 months, respectively, in 55 CA controls, but the differences were not statistically significant (P ¼ 0.46 and 0.41, respectively). In contrast, we have earlier reported inferior PFS in 32 AA patients after auto-SCT compared with 54 non-AA patients. 11 In our earlier report, early relapses after auto-SCT did not have impact on the OS in AA population compared with non-AA population. To further study the outcomes after auto-SCT in AA with MM and the influence of pre and post transplant prognostic variables known to be important for CA on these outcomes, we combined the data from three institutions to create the largest cohort of AA patients who underwent auto-SCT for MM reported to date.
Patients and methods

Patients
Between February 1996 and June 2006, 101 consecutive AA patients with symptomatic MM underwent auto-SCT at Henry Ford Hospital (Center-1), Karmanos Cancer Institute (Center-2) and University of Michigan (Center-3). Approval from the institutional review board (IRB) was obtained before chart review. The clinical characteristics of the patients are shown in Table 1 .
Induction therapy, stem cell mobilization and high-dose therapy The majority (76) of patients received at least one or two regimens of initial induction therapy and 22 patients received more than two regimens. Induction therapy data ) followed by G-CSF (10 mg/kg s.c. injection daily). Conditioning regimen was high-dose melphalan 200 mg/M 2 in 87 patients, melphalan 140 mg/M 2 and TBI 1200 cGy in 11 patients, and BU (9.6 mg/kg)/CY (120 mg/kg)/TBI (900 cGy) in three patients.
Response criteria
The best clinical response within 6 months after auto-SCT was assessed on the basis of EBMT standard criteria. 12 CR was defined by the absence of a detectable monoclonal protein in serum or urine on immunofixation and less than 5% plasma cells in the BM biopsy. Disease progression was defined as an increase in serum or urinary monoclonal protein by 25%, or a 25% increase in plasma cell infiltration of the BM in non-secretory myeloma. Relapse from CR was defined by recurrence of monoclonal protein or BM plasmacytosis. ), time from diagnosis to transplant (p9 months vs 49 months), cytogenetics (chromosome 13 deletion vs normal vs other), number of prior treatment regimens (p2 vs 42), beta-2 microglobulin (B2M, p3 vs 43), LDH (p300 vs 4300), history of palliative radiation therapy (XRT) for pain control before auto-SCT (yes vs no), conditioning regimen (TBI-based vs non-TBI) and maintenance therapy (yes vs no). Univariate analyses for OS and PFS were computed from the log-rank test. Variables that achieved statistical significance (Po0.10) in the univariate analyses were subsequently included in multivariate analysis for OS and PFS using the Cox regression model.
Statistical analysis
Match pair analysis
To further validate the differences in outcomes, while reducing the effect of the transplant center, we carried out a match pair analysis between AA and CA with respect to age, sex and approximate year of transplant for center-3 patients (37 AA patients).
Results
Patients' characteristics
Patients' characteristics are shown in Table 1 . The clinical characteristics were comparable between the centers except for disease stage and cell dose. More patients with advanced disease were transplanted at center-1 and a higher median CD34 cell dose was infused at center-2. The overall median cell dose infused was 5.5 Â 10 6 /kg CD34-positive cells.
Cytogenetics data were available for 69/101 (68%) patients. Chromosome 13 deletion was detected in 24/69 (35%) patients and 39/69 (56%) patients had normal cytogenetics. Complex cytogenetics was present in 6/69 (9%) patients.
Skeletal bone lesions were present in 74/101 (74%) patients as assessed by skeletal survey or MRI. Palliative XRT for pain control at any time before auto-SCT was given to 39/99 (39%)patients for whom data were available.
Eleven patients received a second transplant either as part of a planned tandem transplant (in 7 patients) or as salvage for progression (3 auto-SCT and 1 reduced intensity allogeneic transplant). These patients were censored for further analysis at the time of second transplant. Thalidomide-based maintenance therapy after auto-SCT was used in 36/98 (36%) patients for whom the history of maintenance therapy was available.
Outcomes Transplant-related mortality was 1% at day 100. Disease status at and after auto-SCT is shown in Table 2 . CR rate improved from 9% (9/28) at the time of auto-SCT to 28% (28/101) after auto-SCT (Table 2 ). In all, 36/101 (36%) patients achieved (CR þ VGPR) after auto-SCT. The median PFS and OS were 15.6 and 50.8 months, respectively (Figures 1a and b) . The median OS from diagnosis was 60 months. There was no statistical difference in survival between centers in terms of PFS (P ¼ 0.77) or OS (P ¼ 0.86).
Influence of pre and post transplant prognostic variables on outcomes
We evaluated the influence of common peritransplant prognostic variables in CA with MM to assess their impact on PFS and OS in AA after auto-SCT. Disease stage at auto-SCT, CR after auto-SCT, LDH, B2M, time to transplant and cytogenetics were not predictive of improved PFS or OS. On univariate analysis, history of palliative XRT before auto-SCT, age 455 years, status at transplant (MR and PD) and CD34 count of p5.5 Â 10 6 /kg infused were predictive of poor PFS (Table 3) . Only history of palliative XRT before auto-SCT was predictive of poor Table 2 Disease status pre-and post-auto-SCT 
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OS among the peritransplant variables analyzed. The PFS was twice as long in patients who never received XRT before auto-SCT as in patients who received palliative XRT (24.2 vs 11.9 months, P ¼ 0.05) (Figure 2a) . Likewise, as shown in Figure 2b , OS was much longer in patients who never received XRT before auto-SCT than in patients who received palliative XRT (68.6 vs 25.3 months, P ¼ 0.0003). On multivariate analysis, both status at transplant and prior palliative XRT were predictive of inferior PFS (P ¼ 0.04 and o0.001, hazard ratio of 1.6 and 3.7, respectively), whereas only early palliative XRT was predictive of poor OS (P ¼ 0.006, Hazard ratio of 2.5; Table 4 ). Finally, there were no statistically significant differences with respect to any of the other characteristics between patients with a history of palliative XRT and those who did not receive palliative XRT before auto-SCT.
Matched pair analysis
There was no statistical difference between AA and CA groups in regard to conditioning regimen, cytogenetics, time to transplant, disease stage and status at transplant. The median PFS and OS in 37 AA (Center-3) was 16 and 68.6 months compared with 38 and 87.8 months in the CA control group in the same center (P ¼ 0.02 and 0.05).
Discussion
This study represents the largest cohort of AA with MM who underwent auto-SCT. In addition, it is the only study published to date that examines the impact of peritransplant variables on the outcomes in this population. OS in AA with MM after auto-SCT seems to be similar to the reported OS after auto-SCT in non-AA patients. African American patients do not seem to be more likely to experience lethal complications after auto-SCT given the low TRM rate of 1%. Contrary to earlier reports, AA patients in our analysis had shorter PFS (15.6 months) than the 21 and 60.5 months reported earlier in two smaller series. 9, 10 This difference may be related to the smaller cohort of patients in these analyses. Furthermore, whereas most of the patients in our series were local residents of southeast Michigan with easy access to the transplant centers, the distance traveled to the transplant centers was not addressed in the report by Verma et al. This might have impacted the frequency of follow-up and resulted in early diagnosis of asymptomatic biochemical relapse as opposed to a late symptomatic relapse. The short PFS observed in the AA patients in this large cohort of patients is consistent with our earlier report. 11 It is further validated as well in the match pair analysis. These early relapses and short PFS did not seem to have any impact on the median OS compared with historical controls in CA, but a trend towards improved survival was found in the matched pair analysis. These differences in the outcomes between studies further address the need for future prospective trials designed to examine potential racial differences.
CR rate after auto-SCT was 28% consistent with other reports in non-AA.
7,15-17 CR after auto-SCT is often used as a surrogate marker of survival and is frequently accepted as a study end point. [18] [19] [20] [21] [22] However, CR after auto-SCT was not predictive of improved OS or PFS in our analysis. Refractory disease at the time of auto-SCT was associated with poor PFS and a trend towards worse OS, consistent with the published literature in non-AA. 23, 24 Chromosome 13 deletions were detected in 35% of the patients with available cytogenetics, comparable to earlier reports in non-AA. 25, 26 Interestingly, history of palliative XRT before auto-SCT was predictive of poor PFS and OS in univariate and 27, 28 At this point, the cause of the inferior outcomes in patients with a history of palliative XRT before auto-SCT is unclear. This observation merits further study in AA and CA, while addressing other variables, including the size, site, number and symptoms of lytic lesions that triggered initiation of palliative XRT before auto-SCT.
We realize that our results are limited by the absence of cytogenetics studies in one-third of the patients and the nature of retrospective analysis. We conclude from this analysis that AA with MM tend to relapse early after auto-SCT; however, it is unclear whether these early relapses affect OS compared with CA. Traditional common prognostic peritransplant variables known in CA with MM may not be applicable to AA with MM. Palliative XRT before auto-SCT for MM may have an adverse prognostic effect, which merits further confirmation.
Finally, future prospective studies are needed to address the potential racial differences in outcomes of MM.
